Table 1

Clinical characteristics of SLE patients

SLEDAI

Sema3A

(ng/ml)

a. Cal

LN

a. dsDNA

Complement

Treatment

C3

C4

1

16

44

+

+

L

L

HCQ; P

2

14

32

+

+

+

L

L

HCQ; P

3

3

82

N

N

HCQ

4

4

63

N

L

P

5

4

69

+

N

N

HCQ; P; AZA

6

4

51

+

N

N

HCQ; Atabrin

7

5

69

+

N

L

HCQ; P

8

8

53

N

L

HCQ; P; AZA

9

6

79

+

+

L

L

HCQ; P; AZA

10

12

44

N

L

HCQ; P; AZA

11

6

65

N

N

HCQ; P

12

9

48

+

N

L

HCQ; P; AZA

13

6

65

+

+

L

L

HCQ; P; AZA

14

3

76

N

L

HCQ; P

15

12

42

+

+

N

L

HCQ; P; AZA

16

8

64

+

+

L

L

HCQ; P;

17

18

38

+

+

+

L

L

HCQ; P; AZA

18

18

33

+

+

+

L

L

HCQ; P; MTX; IVIg

19

4

68

+

N

L

HCQ; P; AZA

20

6

55

N

N

HCQ; P

21

6

60

+

+

N

L

HCQ; P

22

24

20

+

+

+

L

L

HCQ; P; MTX; IVIg

23

5

70

+

N

N

HCQ; P

24

10

50

+

+

+

L

L

HCQ; P; AZA

25

13

36

+

+

+

L

L

HCQ; P;

26

4

65

+

N

N

HCQ;

27

26

26

+

+

+

L

L

HCQ; P; CYC

28

6

61

N

N

HCQ; P; AZA

29

4

63

N

N

HCQ; P; AZA

30

4

59

N

L

HCQ

31

5

58

+

+

N

N

HCQ; P; AZA

32

20

34

+

+

+

L

L

HCQ; P; CYC

a.Cal, anti-cardiolipin; a.dsDNA, anti-double-stranded DNA; AZA, azathioprine; CYC, cyclophosphamide; F, female; HCQ, hydroxychloroquine; IVIg, intravenous immunoglobulin; L, low; LN, lupus nephritis; M, male; MTX, Methotrexate; N, normal; P, prednisone; Sema3A, semaphorin 3A.

Vadasz et al. Arthritis Research & Therapy 2012 14:R146   doi:10.1186/ar3881